Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Saved in:
| Title: | Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma. |
|---|---|
| Authors: | Shui, Lin1 (AUTHOR), Cheng, Ke1 (AUTHOR), Li, Xiaofen1 (AUTHOR), Shui, Pixian2 (AUTHOR), Zhou, Xiaohan1 (AUTHOR), Li, Jian3 (AUTHOR), Yi, Cheng1 (AUTHOR), Cao, Dan1 (AUTHOR) hxcaodan2019@163.com |
| Source: | BMC Cancer. 7/9/2020, Vol. 20 Issue 1, p1-8. 8p. 1 Chart, 1 Graph. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 14712407 |
|---|---|
| DOI: | 10.1186/s12885-020-07126-3 |
